Multicenter Retrospective Analysis of Chemotherapy for Advanced Pancreatic Acinar Cell Carcinoma: Potential Efficacy of Platinum- and Irinotecan-Containing Regimens.

Abstract

OBJECTIVES:

The aim of this multicenter retrospective study was to identify the optimal chemotherapeutic regimen for advanced pancreatic acinar cell carcinoma (PACC).

METHODS:

Fifty-eight patients with histopathologically confirmed advanced PACC who had received chemotherapy between 1996 and 2013 were enrolled. The clinical characteristics of the patients and the treatment efficacy data were collected from the medical records at 16 Japanese institutions, using standardized data collection instrument.

RESULTS:

The most commonly selected treatment regimens were gemcitabine-, fluoropyrimidine-, platinum-, and irinotecan-containing regimens. The overall response rate in the patients who received first-line chemotherapy were 7% and 38%, respectively, and the median overall survival was 13.2 months. When the data for all the treatment lines were aggregated, the response rates to gemcitabine-, fluoropyrimidine-, platinum-, and irinotecan-containing regimens were 7%, 18%, 40%, and 29%, respectively. The overall survival tended to be better in patients who had received a platinum-containing regimen (hazard ratio, 0.50; 95% confidence interval, 0.23-1.11; P = 0.08) or irinotecan-containing regimen (hazard ratio, 0.42; 95% confidence interval, 0.15-1.19; P = 0.09) at least once in the treatment course as compared with those who had not.

CONCLUSIONS:

Our findings suggested that platinum- and irinotecan-containing regimens exhibited some potential efficacy in patients with advanced PACC.

• Authors: Hideaki Takahashi, Masafumi Ikeda, Satoshi Shiba, Hiroshi Imaoka, Akiko Todaka, Kazuhiko Shioji, Kei Yane, Yasushi Kojima, Satoshi Kobayashi, Akinori Asagi, Masato Ozaka, Ryoji Takada, Yoshikuni Nagashio, Shigeru Horiguchi, Akiyoshi Kasuga, Eiichiro Suzuki, Takeshi Terashima, Makoto Ueno, Chigusa Morizane, Junji Furuse
• Journal: Pancreas (Pancreas) Vol. 50 Issue 1 Pg. 77-82 (01 01 2021) ISSN: 1536-4828 [Electronic] United States
• PMID: 33370026 (Publication Type: Comparative Study, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc.

Chemical References

• Platinum Compounds
• Irinotecan

Topics

• Adolescent
• Adult
• Aged
• Aged, 80 and over
• Antineoplastic Combined Chemotherapy Protocols (adverse effects, therapeutic use)
• Carcinoma, Acinar Cell (drug therapy, mortality, pathology)
• Child
• Disease Progression
• Female
• Humans
• Irinotecan (adverse effects, therapeutic use)
• Japan
• Male
• Middle Aged
• Pancreatic Neoplasms (drug therapy, mortality, pathology)
• Platinum Compounds (adverse effects, therapeutic use)
• Progression-Free Survival
• Retrospective Studies
• Time Factors
• Young Adult